BioMarin Pharmaceutical Inc. (0HNC.L)
USD 58.91
(-5.27%)
USD 58.91
(-5.27%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 593.09 Million USD | -45.24% |
| 2022 | 1.08 Billion USD | 0.37% |
| 2021 | 1.07 Billion USD | 0.37% |
| 2020 | 1.07 Billion USD | 121.11% |
| 2019 | 486.23 Million USD | -41.45% |
| 2018 | 830.41 Million USD | 2.08% |
| 2017 | 813.52 Million USD | 23.12% |
| 2016 | 660.76 Million USD | -0.23% |
| 2015 | 662.28 Million USD | 0.66% |
| 2014 | 657.97 Million USD | 0.37% |
| 2013 | 655.56 Million USD | 101.8% |
| 2012 | 324.85 Million USD | -6.74% |
| 2011 | 348.32 Million USD | -7.73% |
| 2010 | 377.52 Million USD | -24.05% |
| 2009 | 497.08 Million USD | 0.0% |
| 2008 | 497.08 Million USD | -0.06% |
| 2007 | 497.37 Million USD | 122.1% |
| 2006 | 223.94 Million USD | 5.17% |
| 2005 | 212.92 Million USD | -6.63% |
| 2004 | 228.03 Million USD | 82.43% |
| 2003 | 125 Million USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 3.96 Million USD | 6973.21% |
| 2000 | 56 Thousand USD | -34.12% |
| 1999 | 85 Thousand USD | -15.0% |
| 1998 | 100 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 593.6 Million USD | 0.09% |
| 2024 Q2 | 594.11 Million USD | 0.09% |
| 2024 Q3 | 594.62 Billion USD | 0.09% |
| 2023 Q3 | 592.58 Million USD | -45.38% |
| 2023 FY | 593.09 Million USD | -45.24% |
| 2023 Q4 | 593.09 Million USD | 0.09% |
| 2023 Q1 | 1.08 Billion USD | 0.09% |
| 2023 Q2 | 1.08 Billion USD | 0.09% |
| 2022 Q4 | 1.08 Billion USD | 0.09% |
| 2022 Q3 | 1.08 Billion USD | 0.09% |
| 2022 FY | 1.08 Billion USD | 0.37% |
| 2022 Q1 | 1.08 Billion USD | 0.09% |
| 2022 Q2 | 1.08 Billion USD | 0.09% |
| 2021 Q3 | 1.07 Billion USD | 0.09% |
| 2021 Q4 | 1.07 Billion USD | 0.09% |
| 2021 FY | 1.07 Billion USD | 0.37% |
| 2021 Q1 | 1.07 Billion USD | 0.09% |
| 2021 Q2 | 1.07 Billion USD | 0.09% |
| 2020 FY | 1.07 Billion USD | 121.11% |
| 2020 Q3 | 1.07 Billion USD | 0.09% |
| 2020 Q1 | 486.71 Million USD | 0.1% |
| 2020 Q2 | 1.07 Billion USD | 120.5% |
| 2020 Q4 | 1.07 Billion USD | 0.09% |
| 2019 Q3 | 843.61 Million USD | 0.53% |
| 2019 FY | 486.23 Million USD | -41.45% |
| 2019 Q1 | 834.76 Million USD | 0.52% |
| 2019 Q2 | 839.16 Million USD | 0.53% |
| 2019 Q4 | 486.23 Million USD | -42.36% |
| 2018 Q1 | 817.67 Million USD | 0.51% |
| 2018 FY | 830.41 Million USD | 2.08% |
| 2018 Q4 | 830.41 Million USD | 0.52% |
| 2018 Q3 | 826.11 Million USD | 0.52% |
| 2018 Q2 | 821.87 Million USD | 0.51% |
| 2017 Q3 | 1.16 Billion USD | 72.44% |
| 2017 Q1 | 668.43 Million USD | 1.16% |
| 2017 FY | 813.52 Million USD | 23.12% |
| 2017 Q2 | 676.2 Million USD | 1.16% |
| 2017 Q4 | 813.52 Million USD | -30.23% |
| 2016 Q1 | 668 Million USD | 0.86% |
| 2016 Q4 | 660.76 Million USD | 1.16% |
| 2016 FY | 660.76 Million USD | -0.23% |
| 2016 Q3 | 653.17 Million USD | 1.16% |
| 2016 Q2 | 645.68 Million USD | -3.34% |
| 2015 Q1 | 655.49 Million USD | -0.38% |
| 2015 Q2 | 661.49 Million USD | 0.92% |
| 2015 Q4 | 662.28 Million USD | -0.82% |
| 2015 FY | 662.28 Million USD | 0.66% |
| 2015 Q3 | 667.79 Million USD | 0.95% |
| 2014 Q2 | 650.87 Million USD | -1.59% |
| 2014 FY | 657.97 Million USD | 0.37% |
| 2014 Q3 | 656.88 Million USD | 0.92% |
| 2014 Q4 | 657.97 Million USD | 0.17% |
| 2014 Q1 | 661.41 Million USD | 0.89% |
| 2013 Q3 | 78.31 Million USD | -28.69% |
| 2013 Q1 | 109.84 Million USD | -66.19% |
| 2013 Q2 | 109.82 Million USD | -0.02% |
| 2013 FY | 655.56 Million USD | 101.8% |
| 2013 Q4 | 655.56 Million USD | 737.14% |
| 2012 FY | 324.85 Million USD | -6.74% |
| 2012 Q4 | 324.85 Million USD | -0.0% |
| 2012 Q1 | 324.87 Million USD | -6.73% |
| 2012 Q2 | 324.86 Million USD | -0.0% |
| 2012 Q3 | 324.86 Million USD | -0.0% |
| 2011 Q4 | 348.32 Million USD | -0.0% |
| 2011 FY | 348.32 Million USD | -7.73% |
| 2011 Q3 | 348.33 Million USD | -7.73% |
| 2011 Q1 | 377.52 Million USD | 0.0% |
| 2011 Q2 | 377.52 Million USD | -0.0% |
| 2010 Q3 | 497.08 Million USD | 0.0% |
| 2010 FY | 377.52 Million USD | -24.05% |
| 2010 Q2 | 497.08 Million USD | 0.0% |
| 2010 Q1 | 497.08 Million USD | 0.0% |
| 2010 Q4 | 377.52 Million USD | -24.05% |
| 2009 Q4 | 497.08 Million USD | 0.0% |
| 2009 FY | 497.08 Million USD | 0.0% |
| 2009 Q1 | 497.08 Million USD | 0.0% |
| 2009 Q2 | 497.08 Million USD | 0.0% |
| 2009 Q3 | 497.08 Million USD | 0.0% |
| 2008 Q4 | 497.08 Million USD | -0.03% |
| 2008 Q3 | 497.24 Million USD | -0.0% |
| 2008 Q1 | 497.3 Million USD | -0.02% |
| 2008 Q2 | 497.24 Million USD | -0.01% |
| 2008 FY | 497.08 Million USD | -0.06% |
| 2007 FY | 497.37 Million USD | 122.1% |
| 2007 Q1 | 240.44 Million USD | 7.37% |
| 2007 Q2 | 564.7 Million USD | 134.86% |
| 2007 Q3 | 564.32 Million USD | -0.07% |
| 2007 Q4 | 497.37 Million USD | -11.86% |
| 2006 Q2 | 367.31 Million USD | -0.14% |
| 2006 Q3 | 293.08 Million USD | -20.21% |
| 2006 Q1 | 367.83 Million USD | 72.76% |
| 2006 FY | 223.94 Million USD | 5.17% |
| 2006 Q4 | 223.94 Million USD | -23.59% |
| 2005 FY | 212.92 Million USD | -6.63% |
| 2005 Q3 | 214.44 Million USD | -0.7% |
| 2005 Q2 | 215.96 Million USD | 49.35% |
| 2005 Q1 | 144.6 Million USD | -36.59% |
| 2005 Q4 | 212.92 Million USD | -0.71% |
| 2004 FY | 228.03 Million USD | 82.43% |
| 2004 Q1 | 125 Million USD | 0.0% |
| 2004 Q2 | 128.77 Million USD | 3.02% |
| 2004 Q3 | 222.06 Million USD | 72.44% |
| 2004 Q4 | 228.03 Million USD | 2.69% |
| 2003 Q4 | 125 Million USD | 0.0% |
| 2003 Q3 | 125 Million USD | 0.0% |
| 2003 Q2 | 125 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | 125 Million USD | 0.0% |
| 2002 Q1 | 3.5 Million USD | -11.56% |
| 2002 FY | - USD | -100.0% |
| 2002 Q4 | - USD | -100.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 Q3 | 2.91 Million USD | 0.0% |
| 2001 Q4 | 3.96 Million USD | 2613.01% |
| 2001 Q2 | 198 Thousand USD | 321.28% |
| 2001 Q1 | 47 Thousand USD | -16.07% |
| 2001 Q3 | 146 Thousand USD | -26.26% |
| 2001 FY | 3.96 Million USD | 6973.21% |
| 2000 Q2 | 68 Thousand USD | -11.69% |
| 2000 Q3 | 63 Thousand USD | -7.35% |
| 2000 FY | 56 Thousand USD | -34.12% |
| 2000 Q1 | 77 Thousand USD | -9.41% |
| 2000 Q4 | 56 Thousand USD | -11.11% |
| 1999 Q3 | 100 Thousand USD | -99.62% |
| 1999 Q2 | 26.1 Million USD | 26000.0% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1999 FY | 85 Thousand USD | -15.0% |
| 1999 Q4 | 85 Thousand USD | -15.0% |
| 1998 FY | 100 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -355.999% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -940.737% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -52.916% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -1198.0% |
| bluebird bio, Inc. | 224.41 Million USD | -164.28% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -1499.544% |
| Imunon, Inc. | 1.13 Million USD | -51958.162% |
| Editas Medicine, Inc. | 24.37 Million USD | -2333.51% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 95.422% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 69.978% |
| Myriad Genetics, Inc. | 130.9 Million USD | -353.09% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -129.615% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1686.646% |
| Verastem, Inc. | 40.08 Million USD | -1379.556% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 92.627% |
| Waters Corporation | 2.3 Billion USD | 74.275% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 98.106% |
| Biogen Inc. | 7.18 Billion USD | 91.749% |
| Nektar Therapeutics | 112.62 Million USD | -426.61% |
| Perrigo Company plc | 3.63 Billion USD | 83.674% |
| Dynavax Technologies Corporation | 252.41 Million USD | -134.965% |
| Illumina, Inc. | 1.48 Billion USD | 60.168% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -18213.139% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -59209.5% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -241.344% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -2419.627% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -1669.64% |
| Evolus, Inc. | 120.35 Million USD | -392.772% |
| Adicet Bio, Inc. | 17.7 Million USD | -3250.251% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -19193.917% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 78.057% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -18.253% |
| FibroGen, Inc. | 89.69 Million USD | -561.221% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 78.315% |
| OPKO Health, Inc. | 222.03 Million USD | -167.119% |
| Homology Medicines, Inc. | 43.17 Million USD | -1273.668% |
| Geron Corporation | 35.05 Million USD | -1592.092% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 74.687% |
| Exelixis, Inc. | 189.94 Million USD | -212.247% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -63264.85% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -513.037% |
| Zoetis Inc. | 6.56 Billion USD | 90.964% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -233.068% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -13373.308% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 18.16% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1634.703% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 57.647% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 47.63% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 60.441% |
| Blueprint Medicines Corporation | 610.96 Million USD | 2.924% |
| Insmed Incorporated | 1.19 Billion USD | 50.3% |
| TG Therapeutics, Inc. | 100.11 Million USD | -492.396% |
| Incyte Corporation | 29.16 Million USD | -1933.794% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -32.832% |